Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China.

MLA

Yuting Yan, et al. “Real-World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B-Cell Lymphoproliferative Diseases Treated with BTK Inhibitors in China.” Frontiers in Immunology, July 2023, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fimmu.2023.1184395.

APA

Yuting Yan, Rui Lv, Tingyu Wang, Ying Yu, Yanshan Huang, Wenjie Xiong, Yuxi Li, Weiwei Sui, Qi Wang, Wenyang Huang, Gang An, Dehui Zou, Jianxiang Wang, Lugui Qiu, & Shuhua Yi. (2023). Real-world treatment patterns, discontinuation and clinical outcomes in patients with B-cell lymphoproliferative diseases treated with BTK inhibitors in China. Frontiers in Immunology, 1–11. https://doi.org/10.3389/fimmu.2023.1184395

Chicago

Yuting Yan, Rui Lv, Tingyu Wang, Ying Yu, Yanshan Huang, Wenjie Xiong, Yuxi Li, et al. 2023. “Real-World Treatment Patterns, Discontinuation and Clinical Outcomes in Patients with B-Cell Lymphoproliferative Diseases Treated with BTK Inhibitors in China.” Frontiers in Immunology, July, 1–11. doi:10.3389/fimmu.2023.1184395.